Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung

Vladimir Lazar*, Jacques Raynaud, Shai Magidi, Catherine Bresson, Jean François Martini, Susan Galbraith, Fanny Wunder, Amir Onn, Gerald Batist, Nicolas Girard, Ulrik Lassen, C. S. Pramesh, Amal Al-Omari, Sadakatsu Ikeda, Guy Berchem, Jean Yves Blay, Benjamin Solomon, Enriqueta Felip, Josep Tabernero, Eitan RubinThierry Philip, Angel Porgador, Ioana Berindan-Neagoe, Richard L. Schilsky, Razelle Kurzrock

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: SARS-CoV-2 (COVID-19) elicits a T-cell antigen-mediated immune response of variable efficacy. To understand this variability, we explored transcriptomic expression of angiotensin-converting enzyme 2 (ACE2, the SARS-CoV-2 receptor) and of immunoregulatory genes in normal lung tissues from patients with non-small cell lung cancer (NSCLC). Methods: This study used the transcriptomic and the clinical data for NSCLC patients generated during the CHEMORES study [n = 123 primary resected (early-stage) NSCLC] and the WINTHER clinical trial (n = 32 metastatic NSCLC). Results: We identified patient subgroups with high and low ACE2 expression (p = 1.55 × 10−19) in normal lung tissue, presumed to be at higher and lower risk, respectively, of developing severe COVID-19 should they become infected. ACE2 transcript expression in normal lung tissues (but not in tumor tissue) of patients with NSCLC was higher in individuals with more advanced disease. High-ACE2 expressors had significantly higher levels of CD8+ cytotoxic T lymphocytes and natural killer cells but with presumably impaired function by high Thymocyte Selection-Associated High Mobility Group Box Protein TOX (TOX) expression. In addition, immune checkpoint-related molecules – PD-L1, CTLA-4, PD-1, and TIGIT – are more highly expressed in normal (but not tumor) lung tissues; these molecules might dampen immune response to either viruses or cancer. Importantly, however, high inducible T-cell co-stimulator (ICOS), which can amplify immune and cytokine reactivity, significantly correlated with high ACE2 expression in univariable analysis of normal lung (but not lung tumor tissue). Conclusions: We report a normal lung immune-tolerant state that may explain a potential comorbidity risk between two diseases – NSCLC and susceptibility to COVID-19 pneumonia. Further, a NSCLC patient subgroup has normal lung tissue expressing high ACE2 and high ICOS transcripts, the latter potentially promoting a hyperimmune response, and possibly leading to severe COVID-19 pulmonary compromise.

Original languageEnglish
JournalTherapeutic Advances in Medical Oncology
StatePublished - 2022
Externally publishedYes


FundersFunder number
European Union Sixth Framework
Fundación Merck Salud
Lilly France SAS
National Cancer InstituteP30 P30-CA023100
National Cancer Institute
Novartis Pharmaceuticals Corporation
Sixth Framework Programme
Canadian Institutes of Health ResearchMOP-142281
Canadian Institutes of Health Research
Canadian Cancer Society703811
Canadian Cancer Society
Israel Science Foundation1188/16
Israel Science Foundation
Fondation ARC pour la Recherche sur le Cancer
Instituto de Salud Carlos IIICM15/00255
Instituto de Salud Carlos III
Seventh Framework ProgrammeFP7/2007-2013, 306125
Seventh Framework Programme


    • ACE2 expression
    • COVID-19
    • cancer
    • normal lung
    • transcriptomics


    Dive into the research topics of 'Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung'. Together they form a unique fingerprint.

    Cite this